Digital Scent Device OsmoLink Goes Commercial: Telemedicine Enables 'Smell Diagnosis' for the First Time

Digital Scent Device OsmoLink Goes Commercial: Telemedicine Enables 'Smell Diagnosis' for the First Time

Israeli sensing technology company ScentTech today released the OsmoLink digital scent system, the world's first commercial device capable of capturing, encoding, and remotely reproducing scents. The system includes a scent sensing unit priced at $899 and a scent reproduction unit at $1,299.

OsmoLink's sensing unit contains an array of 432 metal oxide sensors that can identify over 5,000 volatile compounds. The system decomposes scents into molecular-level feature vectors, encodes them digitally, and after network transmission, the reproduction unit reconstructs the scent by precisely mixing 32 base odor molecules.

ScentTech CEO David Rosenberg stated: "Scent is the last human sense to be digitized. OsmoLink makes scent information storable, transmittable, and reproducible, opening entirely new application scenarios."

首批 commercial clients include Mayo Clinic (for remote skin lesion scent diagnosis) and Nestlé (for remote food quality control). Mayo Clinic dermatology chair Lisa Zhang said: "Certain skin lesions have characteristic scents. OsmoLink enables 'smell diagnosis' in telemedicine for the first time."

However, scent digitization faces standardization challenges. Olfactory perception is far more subjective than vision or hearing—the same scent can smell completely different to different people. ScentTech acknowledges this limitation and states it is working with ISO on international standards for scent encoding.